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ABSTRACT 
Background: Osteonecrosis  of the jaw (ONJ) is a chronic complication of bisphosphonate 
therapy, mainly when intravenous, in cancer patients with bone metastases and myeloma. Its 
pathophysiology is not yet fully elucidated; in particular, the molecular/cellular events 
triggering ONJ remain unclear. This complication could result from the effect of 
bisphosphonates released from bone into the soft-tissues, or from osteolysis induced by soft-
tissues directly exposed to bisphosphonates. 
This research investigated the possibility that ONJ may be evocated by changes induced in 
osteoblast activity by factors released by soft-tissue cells exposed to zoledronic acid. 
Methods: An “in vitro” model was used, in which human osteoblast-like MG-63 cells were 
grown in medium conditioned by human keratinocytes NCTC 2544, exposed or not to 
zoledronic acid (5 or 50 µM). 5 µM zoledronic acid was also directly administered to MG-63 
cells. Results: In NCTC 2544 cells, zoledronic acid decreased proliferation via decreased 
hydroxy-3-methyl-glutaryl-CoA reductase, suggesting that a decrease of healing capability 
can occur in case of injury. An increased pro-inflammatory potential was also observed. 
Osteoblasts grown in medium conditioned in presence of zoledronic acid showed decreased 
proliferation and osteogenic properties, and increased ability to induce osteoclast 
differentiation and inflammatory process. Zoledronci acid direcly administered to MG-63 
modulated only some parameters and in a lesser extent. 
Conclusions: The research evidenced, for the first time, the direct involvement of epithelial 
cells in zoledronic-acid-triggered molecular mechanisms leading to osteonecrosis of the jaw, 
by modulating both osteoblast and osteoclast properties. 
 
 
 
 3
 
INTRODUCTION 
 
Osteonecrosis of the jaw (ONJ) is a chronic complication of bisphosphonate (BP) therapy, 
mainly when intravenous, in cancer patients with bone metastases and myeloma. First 
described in 2003, the ONJ incidence ranges from 1.3% to 19%, the highest frequency being 
in mandible (1-3). The most commonly reported associated event is tooth extraction, but 
dental implants, mandibular exostoses, periodontal disease, and local trauma have also been 
described as preceding ONJ (4,5). Among BPs, zoledronic acid is a nitrogen-containing drug 
of the third generation, and is one of the most potent available (6,7). At present, the 
pathophysiological mechanisms underlying ONJ are not yet elucidated, but the fact that it 
occurs spontaneously suggests a multifactorial pathogenesis. 
BPs appear to affect intracortical bone mandible remodeling, as evidenced in skeletally-
mature beagle dogs after 3 years of daily oral treatment with alendronate. Suppression of 
remodeling could allow accumulation of nonviable osteocytes. Moreover, BPs also possess 
anti-angiogenic effect, which probably compromised post-extraction healing (8). The above 
reported effect of BPs could act in a synergic manner in the jaw where, alongside marked 
vascularity, bone turnover is high. 
An important and as yet unsolved problem concerns the ONJ initiation: this complication 
could result from the effect on the soft-tissues of BPs released from the bone, or might be due 
to osteolysis triggered by soft-tissues exposed to BPs. As the name implies, ONJ is assumed 
to be primarily a bone condition. A recent study reported that zoledronic acid, released from 
the bone, affects oral mucosa, inducing early apoptosis and subsequently reducing cell growth 
(9). 
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Little research has as yet deeply examined the true role of soft-tissues in ONJ induction. The 
present research examined the possibility that ONJ is evocated by changes induced in 
osteoblast activity by factors released by epithelial cells exposed to zoledronic acid. For this 
purpose, an “in vitro” model was developed, in which human osteoblast-like MG-63 cells 
were grown in culture medium conditioned by human keratinocytes NCTC 2544, exposed or 
not to zoledronic acid. Parameters relating to proliferation, viability, inflammation, and 
mevalonate pathway were examined. 
 
 
MATERIALS AND METHODS 
 
Cell treatments 
Human keratinocytes NCTC 2544 were seeded (20,000/cm2) in modified Eagle’s medium 
(MEM) supplemented with 2 mM L-glutamine, 1% (v/v) antibiotic/antimycotic solution, 1 
mM sodium pyruvate and 10% (v/v) fetal bovine serum (FBS), and maintained at 37°C in a 
5% CO2 atmosphere. Twenty-four hours after seeding, NCTC cells were exposed to 
zoledronic acid (5or 50 µM) dissolved in PBS. After 48 hours, medium was removed from 
NCTC cells, centrifuged at 3000 rpm per 10 min (centrifuge J-6B Beckman, Brea, CA, USA), 
and used to grow human osteoblast-like cells MG-63. These cells were chosen because, even 
if derived form human osteosarcoma, they are considered very similar to normal osteoblasts 
and usually used in biocompatibility studies. 
MG-63 cells were seeded 20,000/cm2 in modified Eagle’s medium (MEM) supplemented 
with 2 mM L-glutamine, 1% (v/v) antibiotic/antimycotic solution, 1 mM sodium pyruvate and 
10% (v/v) FBS. After 24 hours, culture medium was removed and replaced with medium 
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conditioned by NCTC 2544 cells for 48 hours. Analyses on MG-63 cells and culture media 
were carried out after a further 48 hours. 
When zoledronic acid was directly added to MG-63 cells, cells were seeded 20,000/cm2 in 
modified Eagle’s medium (MEM) supplemented with 2 mM L-glutamine, 1% (v/v) 
antibiotic/antimycotic solution, 1 mM sodium pyruvate and 10% (v/v) FBS. After 24 hours, 
zoledronic acid was added at the final concentration 5 µM. Analyses were carried out after a 
further 48 hours. 
 
Cell growth and viability 
Cells present in monolayer and culture medium were counted using a Burker chamber. 
Viability was determined as lactate dehydrogenase (LDH) release in the medium. LDH 
activity was assessed spectrophotometrically after medium centrifugation at 600 x g for 10 
min, and expressed as nmoles NADH oxidized//min/ml of medium (10). 
 
Flow cytometry 
The percentage of cells with hypodiploid content of DNA, typical of apoptotic cells (sub 
G0/G1 peak), was evaluated by determining the DNA content through propidium iodide 
staining, as described elsewhere (11). 
 
Real-time polymerase chain reaction (real-time PCR) 
Total RNA was extracted from NCTC 2544, MG-63 cells grown in the conditioned medium 
and MG-63 cells directly exposed to zoledronic acid with a RNEasy® Mini Kit (Qiagen, 
GmbH, Germany) following the manufacturer’s protocol. One µg RNA was reverse 
transcripted using the High Capacity cDNA Archive kit (Applied Biosystems, Foster City, 
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CA, USA). Real-time PCR was performed using IQ™ SYBRGreen Supermix (Bio-rad, 
Hercules, CA) in a iCycler system (Bio-Rad, Hercules, CA ). 
Each sample was tested three times. The changes were quantified as relative expression 
compared to that of corresponding control cells, and calculated as 2-∆∆Ct, where ∆Ct = 
Ctsample - CtGAPDH and ∆∆Ct = ∆Ctsample - ∆CtT0. 
 
ELISA analysis 
Cytokines (IL-6, IL-1β and TNF-α) were evaluated in the culture medium of NCTC 2544 or 
MG-63 cells using the Enzyme Linked Immuno Sorbent Assay (Bender Medsystems, Vienna, 
Austria). 
 
Statistical analysis 
Data are expressed as means ± S.D. The significance of differences between group means was 
assessed by variance analysis, followed by the Newman-Keuls test (p < 0.05). 
 
 
RESULTS 
 
The effect of zoledronic acid on growth and viability of NCTC cells is reported in Figure 1. 
Exposure to this BP decreased cell proliferation in a dose-dependent manner, inhibition being 
12.1 % and 37.8%, respectively, in the presence of 5 and 50 µM zoledronic acid. The viability 
determination showed that zoledronic acid did not significantly induce necrosis, whereas a 
significant increase of apoptotic cell percentage (+35% and +182%, in presence of 5 and 50 
µM zoledronic acid, respectively) was observed. 
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Figure 2 reports the mRNA content of factors involved in regulating inflammation and 
proliferation in NCTC cells exposed to zoledronic acid. With regard to pro-inflammatory 
cytokines, no change was observed in IL-1β, whereas a significant increase was observed in 
TNF-α (+90% and +130%, for 5 and 50 µM zoledronic acid, respectively). Similarly, ELISA 
determination of IL-1β and TNF-α release in the culture medium confirmed no change for the 
former and an increase for the latter (data not shown). 
In Figure 2 is also reported the significant decrease found in the mRNA content of PPARα 
(peroxisome proliferation-activated receptor) and HMGR (hydroxy-3-methyl-glutaryl-CoA 
reductase) in the presence of both zoledronic acid concentrations. 
MG-63 cells grown in medium conditioned by zoledronic acid-exposed NCTC 2544cells 
showed decreased cell numbers versus those grown in medium conditioned by unexposed 
NCTC 2544 cells (Figure 3). The decrease was dose-dependent: the percentage inhibition was 
20.8 and 60.0%, in presence of 5 or 50 µM zoledronic acid, respectively. In MG-63 cells 
grown in medium conditioned by NCTC cells exposed to BP, no significant induction of 
necrosis, andapoptosis was observed. The number of MG-63 cells directly exposed to 5 µM 
zoledronic acid for 48 hours was significantly reduced in comparison with all other 
experimental groups. No change was observed in viability. 
Figure 4 shows the mRNA content of inflammatory parameters and molecules involved in 
regulation of bone homeostasis in MG-63 cells. A significant increase of the pro-
inflammatory cytokines IL-1β (+220%), IL-6 (+320%) and IL-8 (550%) was evidenced in 
MG-63 cells grown in the medium conditioned by NCTC 2544 cells exposed to 50 µM 
zoledronic acid; on the contrary, TGF-β2 decreased significantly (-90%). With regard to 
markers of bone homeostasis, the expression of BMP-4  was significantly reduced (-50%) in 
presence of both concentrations used; ALP was significantly reduced (-90%)only in presence 
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of the highest BP concentration. A significant increase of RANK ligand (RANKL) occurred, 
whereas osteoprotegerin (OPG) mRNA was increased, even if in a no significant way . 
In MG-63 cells directly exposed to 5 µM zoledronic acid no significant change was observed 
in IL-1β, IL-8, ALP and OPG mRNA content in comparison with control cells and cells 
grown in medium conditioned by NCTC 2544 cells in presence of 5 µM zoledronic acid.  
IL-6 mRNA content was similar to that of control cells and lower than that in MG-63 cells 
grown in medium conditioned by NCTC 2544 cells in presence of zoledronic acid. 
With regard to TGF-β2, the mRNA content was increased in comparison with control cells 
(+30%) and much more in comparison with MG-63 cells grown in medium conditioned by 
NCTC 2544 cells in presence of zoledronic acid (about 330%). The expression of RANK-L 
was increased in a no significant way in comparison with control cells, and it was lower than 
in MG-63 cells grown in medium conditioned by NCTC 2544 cells in presence of zoledronic 
acid. 
 
DISCUSSION 
 
Despite the significant incidence of ONJ, and the increasing interest in elucidating its patho-
physiology, the underlying molecular mechanisms are still only partially known. In particular, 
“in vivo” observations do not contribute to understanding the mutual influence between soft-
tissues and bone, in triggering ONJ. At the present, experimental studies reported in the 
literature (12-14) mainly investigated the direct effect of BPs on epitellial cells, not the 
consequences that soft-tissue exposition to BPs can trigger on surrounding microenvironment. 
For this reason, our “in vitro” model aimed to investigate in depth the signal transduction 
pathways activated by zoledronic acid in the soft-tissues that may modify 
osteoblast/osteoclast activities. In particular, cell proliferation and viability, and the 
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production of inflammation mediators and molecules responsible for osteoclast activation, 
were evaluated. 
The results regarding NCTC 2544 cells showed zoledronic acid to decrease cell proliferation, 
also inducing an increase in apoptosis in presence of highest zoledronic acid concentration 
used. The reduction of cell proliferation is probably mediated by the decreased expression of 
HMGR, which is the rate-controlling enzyme of the mevalonate pathway that produces both 
cholesterol and isoprenoids, molecules essential for cell proliferation (15). The reduced 
proliferation capacity of soft-tissue after exposure to BPs suggests that BP treatment 
significantly decreases its healing ability after injury, being this crucial in case of ONJ 
consequent to extraction or other invasive procedure. 
Another important finding was that zoledronic acid increased the “pro-inflammatory 
potential” of NCTC 2544 cells: in treated cells, PPARα decreased, while TNFα increased. 
PPARα is a ligand-activated transcription factor, and a member of the nuclear-hormone 
receptor superfamily. Evidence showed that PPARα plays a beneficial role in reducing 
inflammation. Activation of this receptor appears to influence both acute and chronic 
inflammatory disorders involving neutrophils and macrophages (16). In our experimental 
protocol, the decrease of this well-known anti-inflammatory factor was coupled with an 
increase of pro-inflammatory TNFα, both contributing to generating a “pro-inflammatory 
microenvironment” that might be crucial in ONJ pathogenesis. 
The results relating to osteoblasts, grown in medium conditioned by zoledronic-acid-exposed 
NCTC 2544 cells, showed that changes in the culture microenvironment, due to this BP, 
decrease osteoblast proliferation and osteogenic properties, while increasing the cells’ ability 
to induce osteoclast differentiation and inflammatory processes. These observations 
demonstrate, for the first time, that exposing soft-tissues to zoledronic acid significantly 
increases production of pro-inflammatory factors, and decreases that of anti-inflammatory 
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ones. In turn, this affects osteoblast properties: osteoblasts grown in culture medium 
conditioned in presence of zoledronic acid showed reduced proliferation, which translated 
into a reduced regenerating ability during the healing process. This reduction could be 
determinant in the case of tooth extraction, when bone must be regenerated. 
Osteoblasts grown in culture medium conditioned in presence of zoledronic acid also showed 
a reduced expression of BMP-4, TGFβ2 and ALP, indicating a decreased ability to produce 
bone, a fundamental event in tooth socket healing. The decrease in TGFβ2 could also be 
important in reducing angiogenesis process during healing process. In fact, other than to 
stimulate osteoblast proliferation and differentiation, and extracellular matrix production, this 
subtype can induce VEGF expression (17). 
Moreover, in these osteoblasts, an increased expression of RANKL (a factor involved in 
stimulating osteoclast activation) occurred. This observation strongly suggests that altered 
bone remodeling in ONJ could be due partly to the increased soft-tissue-mediated 
osteoclastogenic properties of osteoblasts. 
Results from experiments where MG-63 cells have been directly treated with zoledronic acid 
evidenced that this experimental condition only partially affect osteoblast properties, as 
regards osteogenic and osteoclastogenic properties. Moreover, zoledronic acid only partially 
increases IL-6 expression. 
Since BP-induced osteonecrosis only occurs in the jaw bones, the results of this research 
appear to indicate that the effect of BPs on soft-tissues plays an important role, both in 
reducing the regenerative capability of both soft-tissues and bone, and in increasing bone 
remodeling via induction of osteoclast differentiation and activation. These changes are 
particularly negative in cases of tooth extraction and other events determining bone exposure. 
It may be hypothesized that ONJ occurs in consequence of the close contact between soft-
tissues and bone, a condition not occurring in other body districts. In this anatomic condition, 
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it is possible that BPs accumulated in the bone and released in not-toxic amount affect soft-
tissue properties, these in turn modulating osteoblast and osteoclast functions. 
In conclusion, this research evidenced the possible direct involvement of the soft-tissues in 
zoledronic acid-triggered molecular mechanisms leading to ONJ. It should be noted that 
exposing epitellial cells to zoledronic acid can affect the properties of epithelial cells 
themselves, of osteoblasts and osteoclasts, all of which contribute to the onset of ONJ. 
The experimental model used could also be useful to investigate other aspects of this complex 
oral disease. 
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Figure legends 
 
Figure 1. Effect of zoledronic acid on NCTC 2544 cell proliferation and viability. 
Cells were treated with zoledronic acid for 48 hours. Data are means ± S.D. from 4 
experiments. For each panel, means with different letters are significantly different from one 
another (p<0.05) as determined by analysis of variance followed by post-hoc Newman-Keuls 
analysis. 
C, control cells; 5, cells treated with 5 µM zoledronic acid; 50, cells treated with 50 µM 
zoledronic acid. 
 
Figure 2. mRNA content of IL-1β, TNF-α, PPARα and HMGR in NCTC 2544 cells treated or 
not with zoledronic acid for 48 hours. 
Data are means ± S.D. from 4 experiments. For each parameter, means with different letters 
are significantly different from one another (p<0.05) as determined by analysis of variance 
followed by post-hoc Newman-Keuls analysis. 
C, control cells; 5, cells treated with 5 µM zoledronic acid; 50, cells treated with 50 µM 
zoledronic acid. 
 
Figure 3. Effect of medium conditioned by NCTC 2544 cells exposed or not to zoledronic 
acid, and of direct administration of zoledronic acid on proliferation and viability of MG-63 
cells. 
MG-63 cells were exposed to conditioned medium or to zoledronic acid for 48 hours. Data are 
means ± S.D. from 4 experiments. For each panel, means with different letters are 
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significantly different from one another (p<0.05) as determined by analysis of variance 
followed by post-hoc Newman-Keuls analysis. 
C, MG-63 control cells; 5 CM, MG-63 cells grown in medium conditioned in presence of 5 
µM zoledronic acid; 50, MG-63 cells grown in medium conditioned in presence of 50 µM 
zoledronic acid; 5 ZA, MG-63 cells directly exposed to 5 µM zoledronic acid. 
 
Figure 4. mRNA content of inflammatory, osteogenic, and osteoclastogenic parameters in 
MG-63 cells grown in medium conditioned by NCTC 2544 cells exposed or not to zoledronic 
acid for 48 hours, and in MG-63 cells directly exposed to zoledronic acid. 
Data are means ± S.D. from 4 experiments. For each parameter, means with different letters 
are significantly different from one another (p<0.05) as determined by analysis of variance 
followed by post-hoc Newman-Keuls analysis. 
C, MG-63 control cells; 5 CM, MG-63 cells grown in medium conditioned in presence of 5 
µM zoledronic acid; 50, MG-63 cells grown in medium conditioned in presence of 50 µM 
zoledronic acid; 5 ZA, MG-63 cells directly exposed to 5 µM zoledronic acid. 
 16
 
 
 
 
